ÂÜÀòÂÒÂ×

Cheryl Chin has a wealth of experience in the healthcare and biotechnology industries. Cheryl began their career in 1999 as the Oncology Marketing Director at ALZA Corporation, where they were responsible for developing branding, positioning and messaging for promotional materials, speaker presentations and CME educational materials. In 2001, they joined Johnson & Johnson as the Director of Early Commercial Input for Oncology therapeutics, where they performed market research to define the patient journey, unmet medical needs and customer priorities. In 2008, they moved to Crescendo Bioscience as the Senior Director and Director of Market Strategy, where they created Vectra market assessments, pre-launch market strategies and commercialization plans. From 2014 to 2022, they worked at Myriad Genetics in various roles, including Senior Director of Alliance Management, where they directed all Myriad activities for a Pfizer partnership and facilitated joint decision-making for inclusion of Vectra data in Pfizer scientific publications. Cheryl also served as Senior Director of Alliance Management for a Vectra Phlebotomy project, leading decision-making for three technology suppliers co-developing a novel blood collection and processing device. Lastly, they were Senior Director of Market Strategy, generating strategic and commercial recommendations for six potential partnerships and in-licensing candidates based on market research, scientific literature and KoL feedback. Currently, they are the VP of Marketing at Exai Bio.

Cheryl Chin holds a Bachelor of Arts in Economics from Northwestern University and a Master of Business Administration with a concentration in Marketing & Finance from the University of Michigan.